ELYSIUM CELL BIO ITA
SOCIAL
ADDRESS
via Gaetano Salvatore, 486
Napoli
80145
Italia
Presso CEINGE Biotecnologie Avanzate Franco Salvatore scarl
P.I. 10204541212
ELYSIUM CELL BIO ITA
A SPIN-OFF OF UNIVERSITY FEDERICO II OF NAPLES
C/O CEINGE BIOTECNOLOGIE AVANZATE
ITALIAN YOU TUBE PRESENTATION
WHO WE ARE
Elysium Cell Bio ITA is an academic spin-off accredited by the University of Naples Federico II, founded on December 1, 2023. It is based at CEINGE Advanced Biotechnology in Naples and is led by a team of researchers specialized in genetics, genomics, and translational research, aiming to transform laboratory discoveries into clinical and commercial applications. The company focuses on the development of innovative diagnostic and therapeutic tools, addressing unmet clinical needs in the fields of virology, oncology, nutraceuticals, and regenerative medicine. The multidisciplinary team works in synergy to accelerate technology transfer and the commercialization of the developed solutions.
MISSION: "FROM IDEA TO MARKET"
Elysium Cell Bio ITA is committed to bridging the gap between academic research and clinical applications, translating scientific discoveries into tangible health solutions. The goal is to provide diagnostic tools, innovative drugs, and natural treatments to improve patients' quality of life, contributing to innovation in biotechnology and life sciences.
RESEARCH & DEVELOPMENT AREAS
1-Molecular Diagnostics and Virology
2-Innovative Cancer Therapies and Rigenerative Medicine
3-Nutraceutical and Natural Compounds therapies
FOUNDING MEMBERS
Prof. Massimo Zollo – CEO & Founder, expert in Medical Genetics and Molecular Oncology.
Dr. Veronica Ferrucci – Co-Founder, responsible for the development of nutraceutical compounds.
SCIENTIFIC LEADERSHIP AND ACADEMIC PARTNERS
Prof. Massimo Zollo – Geneticist, expert in Medical Genetics and Molecular Oncology.
Dr. Veronica Ferrucci – Geneticist, expert in Nutraceuticals, Cosmetics, and Molecular Oncology.
Prof. Roberto Berni Canani – Pediatrician and specialist in Nutraceuticals.
Prof. Ivan Gentile – Infectious disease specialist, expert in Clinical Virology.
Prof. Vincenzo Diego Bianchi – Director of the Geriatric Clinical Center of Portici, expert in Geriatrics and Neuroscience.
CEINGE Advanced Biotechnology – Active participant through Prof. Pietro Forestieri (President) and Dr. Mariano Giustino (CEO).
SCIENTIFIC STAFF EXPERT MEMBERS
Dr. Francesco Pellegrino – Expert in Marketing and Pharmaceutical Development.
Dr. Pierluigi Gallo – Expert in the "Wound care", Surgeon and Vulnologist.
FOUNDERS
ZOLLO MASSIMO
Founder and CEO
Massimo Zollo: Full Professor of Genetics at the Faculty of Biotechnological Sciences of the Federico II University of Naples and "Principal Investigator (PI)" with responsibility for a laboratory of molecular genetic research and diagnostics in the human field at the CEINGE "Franco Salvatore" (Centre of Genetic Engineering and Advanced Biotechnology) Center of Excellence of the MIUR. His research carried out abroad and then in Italy (at Washington School of Medicine St. Louis Missouri (USA), Genentech Inc. South San Francisco, California (USA), Applied Biosystems Foster City, California (USA), Telethon Tigem San Raffaele Milano, TIGEM-CNR of Naples and finally at CEINGE / Federico II of Naples) are directed to studies in molecular oncology (breast cancer and brain tumors) and studies on genetic disorders of the central nervous system. Scientific Responsible of the CEINGE TASK FORCE Covid 19 Project, POR FESR CAMPANIA 2014/2020 Priority Axis 1 Research and Innovation FIGHT AGAINST COVID -, Urgent measures regarding the containment and management of the epidemiological emergency from Covid 19. CEINGE TASK FORCE Management decree n.672020 Campania Region (announced with DGR n ° 140 of 03/17/2020; CUP D64I20000380002). To date has produced over 160 scientific papers in international journals, 5 Books with curatorship, generating H-index = 46 and with 12,222 citations. Furthermore, to date Prof. Zollo is the inventor of 19 international patents, 4 of which have given rise to translational research activities and industrial products with Angelini Pharma, Advanced Application "AAA", Thrombogenics and Novartis.
FERRUCCI VERONICA
Founder
Researcher "type A" researcher (RTDA) at the Department of Molecular Medicine and Medical Biotechnology of the University of Naples "Federico II". She has a master's degree in Medical Biotechnology from the Faculty of Biotechnological Sciences of the Federico II University of Naples; PhD in Systems Medicine (Molecular Oncology curriculum) obtained at the European school of molecular medicine SEMM. To date, Dr. Veronica Ferrucci is the author of 32 scientific articles published in international journals with H-index = 12, and is also the creator and owner of n. 7 International Patents in the field of Diagnostics and Therapeutics. Participated in the CEINGE TASK FORCE POR FESR CAMPANIA 2014/2020 Project Priority Axis 1 Research and Innovation FIGHT AGAINST COVID -, Urgent measures regarding the containment and management of the epidemiological emergency from Covid 19 (Managerial Decree n.672020 Campania Region issued with DGR n °140 of 03/17/2020 in the year 2021-2022) coordinated by Prof. Massimo Zollo.
ROBERTO BERNI CANANI
Pediatrics and Nutraceutics
Prof.Dr.Roberto Berni Canani, MD,PhD Chief, Pediatric Allergy Program - Department of Translational Medical Science - Section of Pediatrics Head, Pediatric Allergy Program
Chief, ImmunoNutritionLab - CEINGE Advanced Biotechnologies Research Center
European Laboratory for the Investigation of Food Induced Diseases Task Force on Microbiome Studies University of Naples “Federico II”, Italy. Prof.Roberto Berni Canani is internationally recognized as one of the leading researchers in the area of pediatric pathologies, pediatric gastroenterology, allergology, food induced diseases and human nutrition . He received his MD and PhD degrees from University of Naples “Federico II”, Naples, Italy. Chief of the Pediatric Allergy Program and founder of the ImmunoNutritionLab at Ceinge Advanced Biotechnologies Research Center. He is author of more than 400 publications among scientific paper on international journals, chapters of books and reviews. His publications are widely quoted (collectively more than >24000 citations as at February 2023). Of these, 42 papers have been cited >100 times. H-index score 73. Total impact factor score: >2450. Associate editor of World Journal of Gastroenterology, Journal of Pediatric Gastroenterology and Nutrition, Case Reports in Food Allergy, Journal of Gastroenterology and Hepatology Research, Allergies, International Journal of Autoimmune Disease & Therapy, Edit Symposia, Fontiers in Immunology, Frontiers in Pediatrics. He is member of many national scientific societies (Italian Society of Pediatrics, Italian Society of Pediatric Gastroenterology Hepatology and Nutrition, Italian Society of Pediatric Allergy and Immunology, Italian Society of Infectious Diseases, Italian Society of Pediatric Research).
IVAN GENTILE
Clinical Infettivology and Virology
Prof. Ivan Gentile is Professor of Infectious Diseases at the University of Naples “Federico II” and Director of the Complex Infectious Diseases Operational Unit of the “Federico II” University Hospital of Naples. He is a member of UNESCO Chair of Naples for Health and Development Education Sustainable, as an expert in the Prevention of Infectious Diseases. He is a member of the Technical Committee Ministerial “Health and Environment” (Ministerial Decree 03.24.2023) for the “Plan National Prevention Committee 2020-2025”. His main interests scientific and research are infections associated with multi-resistant germs, vaccinations in frail subjects, chronic viral hepatitis and programs Antimicrobial stewardship also with the use of point-of-care tests. Parallel to the clinical scenarios ed epidemiological events that have occurred, his research activity has ranged over several topics: from viral infections, in particular HCV and HBV with a focus on effectiveness of traditional drugs and new molecules available, to the phenomenon of antibiotic resistance, and its drivers, including the abuse of antibiotic therapies and the possibility of mitigation their improper use with the implantation of point-of diagnostic tests care, the effectiveness of the new drugs available in the fight against this phenomenon. 2020, with the advent of SARS-COV-2, saw his involvement first as a doctor and then as a scientist in the comparisons of COVID-19. To this end, he designed and coordinated several studies on topic, among which are: “COPE Study: COVID-19 post-exposure prophylaxis”; “Impact of early anti-SARS-CoV-2 treatment in vaccinated subjects on clinical progression and the onset of Long-COVID: SAVALO study" and "Effectiveness and safety of Nirmatrelvir/Ritonavir in the treatment of mild/moderate COVID-19 in Italy: a retrospective, multicentre, cohort study”. He conceived, created and participated in several clinical trials, including RCTs, phase II and phase III. Among others, it has designed and was the PI of the phase III RCT: “Iron depletion first of antiviral therapy for HCV”. He is the national coordinator and PI of the study “CEFTObiprole Clinical Use in Real-life”. Engaged in numerous clinical studies also as Principal Investigator, he has an H-index of 40 and a total number of citations of 5623 (Scopus source). He is the author of over 290 Full text scientific contributions in international peer-refereeed journals.
VINCENZO DIEGO BIANCHI
Neurologist and Geratrician
Dr. Vincenzo Diego Bianchi is a specialist in geriatrics and neurophysiopathology, serving as the President of the Board of Directors at Clinica Bianchi in Portici, Italy. He is also part of the clinic's specialized medical staff. In addition to his clinical roles, Dr. Bianchi has contributed to public education on neurological conditions. He is an expert of dementia and the challenges in managing affected patients.
ELYSIUM CELL BIO ITA
SOCIAL
ADDRESS
via Gaetano Salvatore, 486
Napoli
80145
Italia
Presso CEINGE Biotecnologie Avanzate Franco Salvatore scarl
P.I. 10204541212